OTLK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OTLK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Outlook Therapeutics's quarterly cash and cash equivalents declined from Jun. 2023 ($33.71 Mil) to Sep. 2023 ($23.39 Mil) but then stayed the same from Sep. 2023 ($23.39 Mil) to Dec. 2023 ($10.36 Mil).
Outlook Therapeutics's annual cash and cash equivalents increased from Sep. 2021 ($14.48 Mil) to Sep. 2022 ($17.40 Mil) and increased from Sep. 2022 ($17.40 Mil) to Sep. 2023 ($23.39 Mil).
The historical data trend for Outlook Therapeutics's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics Annual Data | |||||||||||||||||||||
Trend | Sep14 | Sep15 | Sep16 | Sep17 | Sep18 | Sep19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Cash And Cash Equivalents | Get a 7-Day Free Trial | 8.02 | 12.54 | 14.48 | 17.40 | 23.39 |
Outlook Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash And Cash Equivalents | Get a 7-Day Free Trial | 52.34 | 43.63 | 33.71 | 23.39 | 10.36 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Outlook Therapeutics (NAS:OTLK) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Thank you for viewing the detailed overview of Outlook Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
Terry Dagnon | officer: Chief Operating Officer | C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Jeff Evanson | officer: Chief Commercial Officer | C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Yezan Munther Haddadin | director | ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844 |
Faisal Ghiath Sukhtian | director | 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844 |
Kurt J Hilzinger | director | 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087 |
Julia A Haller | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Trenary C Russell Iii | director, officer: CEO and President | 1700 E ST ANDREW PLACE, SANTA ANA CA 92705 |
Ghiath M. Sukhtian | director, 10 percent owner | 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844 |
Lawrence A Kenyon | officer: CFO and Secretary | C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512 |
Syntone Ventures Llc | 10 percent owner | 1517 CHAMPLAIN CREST WAY, CARY NC 27513 |
Randy H Thurman | director | 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654 |
Andong Huang | director | C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852 |
Gerd Auffarth | director | C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000 |
Julian S Gangolli | director | 4955 BASELINE AVENUE, SANTA YNEZ CA 93460 |
Gms Ventures & Investments | director | C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007 |
From GuruFocus
By PRNewswire • 11-30-2023
By PRNewswire • 12-14-2023
By PRNewswire • 12-12-2023
By PRNewswire • 12-10-2023
By PRNewswire • 12-27-2023
By PRNewswire • 12-28-2023
By PRNewswire • 12-20-2023
By Business Wire • 01-01-2024
By PRNewswire • 12-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.